For a patient with atrial fibrillation undergoing surgery, how should anticoagulation be managed perioperatively?

For a patient with atrial fibrillation undergoing surgery, how should anticoagulation be managed perioperatively?

• A. Continue anticoagulation through the surgery.
• B. Discontinue anticoagulation permanently.
• C. Switch to antiplatelet therapy instead.
• D. Hold anticoagulation two days before surgery.

Answer: (D)

Balancing bleeding risk with stroke prevention is the core idea in perioperative anticoagulation for atrial fibrillation. Pausing anticoagulation before surgery reduces the chance of excessive bleeding during the operation, while resuming it after surgery helps protect against thromboembolism once hemostasis is achieved. Holding for about two days before the procedure reflects the typical window where the drug’s effect is minimized enough to improve surgical safety, without leaving the patient off protection for an unnecessarily long time. Continuing through surgery would raise bleeding risk too much, and stopping forever would leave the patient vulnerable to stroke. Replacing with antiplatelet therapy isn’t equivalent protection for AF-related embolism and doesn’t address perioperative bleeding risk appropriately. The exact timing depends on the specific anticoagulant and the procedure’s bleeding risk, but a two-day hold is a common, reasonable approach in many cases.

Balancing bleeding risk with stroke prevention is the core idea in perioperative anticoagulation for atrial fibrillation. Pausing anticoagulation before surgery reduces the chance of excessive bleeding during the operation, while resuming it after surgery helps protect against thromboembolism once hemostasis is achieved. Holding for about two days before the procedure reflects the typical window where the drug’s effect is minimized enough to improve surgical safety, without leaving the patient off protection for an unnecessarily long time. Continuing through surgery would raise bleeding risk too much, and stopping forever would leave the patient vulnerable to stroke. Replacing with antiplatelet therapy isn’t equivalent protection for AF-related embolism and doesn’t address perioperative bleeding risk appropriately. The exact timing depends on the specific anticoagulant and the procedure’s bleeding risk, but a two-day hold is a common, reasonable approach in many cases.